NCT05233085View on ClinicalTrials.gov

A Safety Study of AZD4041 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

June 7, 2022

Study Completion Date

June 7, 2022

Conditions
Opioid Use Disorder (OUD)
Interventions
DRUG

AZD4041

Participants will receive oral solution of AZD4041 as stated in arm description.

OTHER

Placebo

Participants will receive oral solution of placebo as stated in arm description.

Trial Locations (1)

h7v 4bc

Research Site, Laval

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Altasciences Company Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY